biotech could be sector for 2024, page-6

https://www.fiercebiotech.com/biotech/astellas-owned-xyphos-offers-800m-kelonias-vivo-delivery-know-how

Astellas buying up, pre-clinic.

Astellas bought Xyphos back in 2019 for $120 million upfront with more than $500 million in biobucks available.

Xyphos linking arms with Kelonia in a research and licensing deal worth north of $800 million. Kelonia will receive a $40 million upfront payment for its work and could snag another $35 million should Xyphos buy into the second. The total amount of milestone and contingency payments is close to $800 million.